1Grillo-Lopez AJ, White CA, Dallaire BK, et al. Rituximab: the first monoelonal antibody approved for the treatment of lymphoma[J]. Curt Pharm Bioteehnol, 2000, 1(1): 1-9.
2Goldblatt F, Isenberg DA. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus[J]. Handb Exp Pharmacol. 2008, (181): 163-181.
3Carr DR, Heffernan MP. Off-label uses of rituximab in dermatology[J]. Dermatol Ther, 2007, 20 (4): 277-287.
4Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B cell-targeted therapy with rituximab in patients with rheumatoid arthritis[J]. N Engl J Med, 2004, 350: 2572-2581.
5Galarza C, Valencia D, Tobon GJ, et al. Should Rituximab be Considered as the First-Choice Treatment for Severe Autoimmune Rheumatic Diseases? [J]. Clin Rev Immunol, 2008, 34 (1): 124-128.
6Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a muhicenter, randomized, double-blind, place- bo-controlled, phase Ⅲ trial evaluating primary efficacy and safety at twenty-four weeks[J]. Arthritis Rheum, 2006, 54 (9): 2793-2806.
7Scheinfeld N. A review of rituximab in cutaneous medicine[J]. Dermatol Online J, 2006, 12 (1): 3.
8Jordan K, Grothey A, Groth W, et al. Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab montherapy[J]. Eur J Haematol, 2005, 74 (3): 263-266.
9Schalk E, Krogel C, Scheinpflug K, et al. Lymphomatoid granulomatosis in a patient with rheumatoid arthritis receiving methotrexate: successful treatment with the anti-CD20 antibody mabthera[J]. Onkologie, 2009, 32(7): 440-441.
10Looney RJ, Anolik JH, Campbell D, et al. B-cell deletion as a novel treatment for systemic lupus erythematosus: a phase Ⅰ/Ⅱ dose-esclation trial of rituximab[J]. Arthritis theum, 2004, 50 (8): 2580-2589.
